Publications - Manish Kohli, M.D.

Back to research profile

1. Tilburt JC, Kim S, Kohli M, Hahbhan M. In Reply. Mayo Clin Proc. 2013 Mar; 88(3):308 Epub 2013 Feb 27.
2. Loprinzi PD, Kohli M. Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006. Mayo Clin Proc. 2013 Jan; 88(1):11-21.
   View PubMed
3. Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc. 2012 Jun; 87(6):540-7.
   View PubMed
4. Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar; 87(3):240-6.
   View PubMed
5. Jones JM, Kohli M, Loprinzi CL. Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl. 2012 Mar; 14(2):193-7. Epub 2012 Jan 30.
   View PubMed
6. Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV. Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med. 2012; 2012:303019. Epub 2012 Feb 22.
   View PubMed
7. Nabhan M, Kim S, Shah N, Bagniewski S, Shi Q, Karnes RJ, Weight C, Davis B, Kohli M, Tilburt J. The relationship of the intensity of post-treatment PSA surveillance and prostate cancer outcomes: Results from a population-based cohort. Mayo Clinic Proceedings. 2012 (in press).
8. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An oberservational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. Journal of Men's Health. 2012; 9(3):182-189 Epub 2012 Aug 11.
9. Kohli M, Qin R, Jimenez R, Dehm SM. Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012; 2012:781459. Epub 2012 Aug 22.
   View PubMed
10. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer. Journal of Men's Health. 2012; 9(3):182-9.
11. Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J. 2011 Sep; 13(3):365-77. Epub 2011 May 11.
    View PubMed
12. Block MS, Kohli M. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. Clin Adv Hematol Oncol. 2011 Apr; 9(4):335-8.
    View PubMed
13. Kohli M, Williams K, Yao JL, Dennis RA, Huang J, Reeder J, Ricke WA. Thrombin expression in prostate: a novel finding. Cancer Invest. 2011 Jan; 29(1):62-7.
    View PubMed
14. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc. 2010 Jan; 85(1):77-86.
    View PubMed
15. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors. 2010; 2(4):e65. Epub 2010 Dec 31.
    View PubMed
16. Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark. 2010; 7(2):101-8.
    View PubMed
17. Yao JL, Ryan CK, Francis CW, Kohli M, Taubman MB, Khorana AA. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009 May; 27(4):430-4.
    View PubMed
18. Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE, Kohli M. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol. 2008 Jan; 16(1):1-6.
    View PubMed
19. Kohli M, Viswamitraa S, Schaefer R, Faas FH, Kumar U. Metastasectomy for isolated bilateral adrenal metastases in hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10):754-5; discussion 756-7.
    View PubMed
20. Kohli M, Schaefer R. Management of solitary palatal metastasis from renal cell carcinoma. Nat Clin Pract Urol. 2006 Jul; 3(7):392-6; quiz following 396.
    View PubMed
21. Alikhan MA, Williams R, Udaya K, Shaefer RF, Viswamitra SC, Kohli M. Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol. 2006 Jun; 13(6):798-800.
    View PubMed
22. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21.
    View PubMed
23. Kohli M, Siegel E, Bhattacharya S, Khan MA, Shah R, Suva LJ. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark. 2006; 2(6):249-58.
    View PubMed
24. Kaushal V, Kohli M, Richard D, Chiles W, Mukunyadzi P. Thrombin and thrombin receptor expression in prostate cancer. Prostate. 2005 Oct 21.
25. Alikhan MA, Spencer HJ, Kohli M. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2, Interferon in Patients with Metastatic Renal Cell Carcinoma. J Clin Oncol. 2005 Sep 1; 23(25):6267-8.
26. Challagundla S, Gokden M, Viswamitra S, Kohli M. Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage. Clin Prostate Cancer. 2005 Sep; 4(2):134-7.
    View PubMed
27. Midathada M, Safar A, Schaefer R, Viswamitra S, Kohli M. Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol. 2005 May; 3(5):425-7.
    View PubMed
28. Kaushal V, Dennis R, Mukunyadzi P, Siegel E, Johnson D, Kohli M. Stage specific expression of VEGF A and D in prostate cancer. Clin Cancer Res. 2005; 11:1-10.
29. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7; 351(15):1513-20.
    View PubMed
30. Kohli M, Mukunyadzi P, Dennis RA, Johnson DE, Kaushal V. COX-2: an inconsistent therapeutic target in prostate cancer. Uro Oncology. 2004 Sep/Dec; 4(3/4):113-8.
31. Kohli M, Zent C, Hutchins LF, Safar M, Dotson, P, Mehta P. The academic hematology-oncology firm: a model for postgraduate cancer education. J Cancer Educ. 2004 Spr; 19(1):45-9.
    View PubMed
32. Kohli M, Khan MA, Mehta P, Hutchins L. Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? J Clin Oncol. 2003 Jun 15; 21(12):2445.
    View PubMed
33. Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost. 2003 Jun; 29(3):301-8.
    View PubMed
34. Kohli M, Kaushal V, Spencer HJ, Mehta P. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology. 2003 Apr; 61(4):765-9.
    View PubMed
35. Kaushal V, Kohli M, Mehta P, Mehta JL. Potential anticancer effects of statins: fact or fiction? Endothelium. 2003; 10(1):49-58.
    View PubMed
36. Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002 Jul 1; 20(13):3042; author reply 3042-3.
    View PubMed
37. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis. 2002 Jan; 13(1):1-5.
    View PubMed
38. Kohli M, Schichman SA, Fink L, Zent CS. Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J. 2000 May; 93(5):469-71.
    View PubMed